February 23, 2024
1 min watch
Save
VIDEO: Specialists await real-world data on faricimab for retinal vein occlusion
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this expert perspective from Hawaiian Eye 2024, Jordan M. Graff, MD, FACS, discusses faricimab for the treatment of retinal vein occlusion.
“I think the biggest thing that we saw with RVO in 2023 was the ability to now have FDA approved use of faricimab,” he said.
Graff, of Barnet Dulaney Perkins Eye Center in Phoenix, said he looks forward to seeing real-world data for the treatment of retinal vein occlusion (RVO) with faricimab and other novel therapies in 2024.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Graff reports receiving research support from Genentech and Regeneron.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.